Verrica Pharmaceuticals Inc. (VRCA)
Automate Your Wheel Strategy on VRCA
With Tiblio's Option Bot, you can configure your own wheel strategy including VRCA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRCA
- Rev/Share 3.2485
- Book/Share -1.7956
- PB -4.2048
- Debt/Equity -0.8285
- CurrentRatio 1.2548
- ROIC -0.6523
- MktCap 71649764.0
- FreeCF/Share -3.0664
- PFCF -2.4622
- PE -2.7543
- Debt/Assets 0.3452
- DivYield 0
- ROE 1.6527
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Verrica Pharmaceuticals Inc. ( VRCA ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Jayson Rieger - President, CEO & Director John Kirby - Interim Chief Financial Officer Conference Call Participants Kevin Gardner Stacy Ku - TD Cowen, Research Division Yuchen Ding - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' Third Quarter 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Read More
Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Verrica Pharmaceuticals (VRCA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read More
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Noah L. Rosenberg, M.D., as Chief Medical Officer.
Read More
About Verrica Pharmaceuticals Inc. (VRCA)
- IPO Date 2018-06-15
- Website https://www.verrica.com
- Industry Biotechnology
- CEO Jayson Rieger
- Employees 71